<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47072">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02090127</url>
  </required_header>
  <id_info>
    <org_study_id>AV-299-13-103S</org_study_id>
    <nct_id>NCT02090127</nct_id>
  </id_info>
  <brief_title>Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient</brief_title>
  <official_title>Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment protocol will serve as a mechanism to continue to provide ficlatuzumab to
      patient 0001-000412, who was previously enrolled under protocol P05538 and whom the
      investigator believes is deriving clinical benefit from ficlatuzumab treatment.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <phase>N/A</phase>
  <study_type>Expanded Access</study_type>
  <study_design>N/A</study_design>
  <condition>Patient 0001-000412 Under Study P05538</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ficlatuzumab</intervention_name>
    <description>humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a Â±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator</description>
    <other_name>AV-299</other_name>
    <other_name>SCH 900105</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Per original P05538 protocol

        Exclusion Criteria:

          -  Per original P05538 protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Francis Payumo</last_name>
    <phone>617-299-5867</phone>
    <email>fpayumo@aveooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>START</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Amita Patnaik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/show/NCT00725634</url>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 14, 2014</lastchanged_date>
  <firstreceived_date>March 14, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
